Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/129964
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Flórez Borges, Paloma | - |
dc.contributor.author | Pérez Lozano, Pilar | - |
dc.contributor.author | García Montoya, Encarna | - |
dc.contributor.author | Miñarro Carmona, Montserrat | - |
dc.contributor.author | Jo, Enric | - |
dc.contributor.author | Manich Bou, Albert | - |
dc.contributor.author | Suñé i Negre, Josep M. (Josep Maria) | - |
dc.date.accessioned | 2019-03-08T13:17:14Z | - |
dc.date.available | 2019-03-08T13:17:14Z | - |
dc.date.issued | 2018-04-24 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://hdl.handle.net/2445/129964 | - |
dc.description.abstract | A preformulation study of an oral lyophilisate with cetirizine dihydrochloride (CTZ) as active ingredient, mannitol and PVP K30 as bulking agents is presented. CTZ shown a humidity content of 0.150% and a spontaneous hygroscopicity of 0.200% (both determined by SeDeM diagram), demonstrating an adequate stability behavior in solid form. A design of experiments (DoE) performed with both mannitol and PVP K30, followed by a simple factorial design (32) has determined the optimum combination of excipients and CTZ, and showed that a higher proportion of PVP K30 was able to prevent metastable forms generated by mannitol. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Public Library of Science (PLoS) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0196049 | - |
dc.relation.ispartof | PLoS One, 2018, vol. 13, num. 4, p. e0196049 | - |
dc.relation.uri | https://doi.org/10.1371/journal.pone.0196049 | - |
dc.rights | cc-by (c) Flórez Borges, Paloma et al., 2018 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) | - |
dc.subject.classification | Administració de medicaments | - |
dc.subject.classification | Medicació oral | - |
dc.subject.classification | Medicaments | - |
dc.subject.classification | Disseny de medicaments | - |
dc.subject.other | Administration of drugs | - |
dc.subject.other | Oral medication | - |
dc.subject.other | Drugs | - |
dc.subject.other | Drug design | - |
dc.title | The Role of SeDeM Characterizing the Active Substance and Polyvynilpyrrolidone Eliminating Metastable Forms in an Oral Lyophilizate - A Preformulation Study. | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 681312 | - |
dc.date.updated | 2019-03-08T13:17:15Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 29689061 | - |
Appears in Collections: | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
681312.pdf | 1.11 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License